Literature DB >> 11809707

Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line.

Christin Tse1, Ruinua H Xiang, Todd Bracht, Susan L Naylor.   

Abstract

The short arm of chromosome 3 has been shown to exhibit high loss of heterozygosity in several types of cancer including ovarian, kidney, lung, and testicular cancers. In particular, overlapping homozygous deletions in lung cancers have been identified in region 3p21.3. Semaphorin 3B, a gene that resides within this region, has been proposed to be involved in tumorigenesis. To address this hypothesis, we have examined the effects of semaphorin 3B on HEY cells, an ovarian cancer cell line. HEY cells expressing semaphorin 3B exhibited a diminished tumorigenicity in BALB/c nu/nu mice. Semaphorin 3B also severely reduced the anchorage independence of HEY cells. These results demonstrate a role for semaphorin 3B in tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809707

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2.

Authors:  Toshihiko Toyofuku; Hong Zhang; Atsushi Kumanogoh; Noriko Takegahara; Fumikazu Suto; Junko Kamei; Kazuhiro Aoki; Masanori Yabuki; Masatsugu Hori; Hajime Fujisawa; Hitoshi Kikutani
Journal:  Genes Dev       Date:  2004-02-20       Impact factor: 11.361

Review 2.  Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer.

Authors:  Atsuko Sakurai; Colleen L Doçi; Colleen Doci; J Silvio Gutkind
Journal:  Cell Res       Date:  2011-12-13       Impact factor: 25.617

Review 3.  Signal transduction in vasculogenesis and developmental angiogenesis.

Authors:  Sunita Patel-Hett; Patricia A D'Amore
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

4.  Downregulation of Semaphorin-3F is associated with poor prognostic significance in osteosarcoma patients.

Authors:  Ming-Han Liu; Wen-Juan Fu; You-Hong Cui; Qiao-Nan Guo; Yue Zhou
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

5.  Expression of semaphorin 6D and its receptor plexin-A1 in gastric cancer and their association with tumor angiogenesis.

Authors:  Yanjie Lu; Qian Xu; Lei Chen; Yanzhen Zuo; Shaochen Liu; Yatao Hu; Xiaoru Li; Yuhong Li; Xiangyang Zhao
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

6.  Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Authors:  Boaz Kigel; Asya Varshavsky; Ofra Kessler; Gera Neufeld
Journal:  PLoS One       Date:  2008-09-26       Impact factor: 3.240

7.  Semaphorin 3B is a 1,25-Dihydroxyvitamin D3-induced gene in osteoblasts that promotes osteoclastogenesis and induces osteopenia in mice.

Authors:  Amelia L M Sutton; Xiaoxue Zhang; Diane R Dowd; Yogendra P Kharode; Barry S Komm; Paul N Macdonald
Journal:  Mol Endocrinol       Date:  2008-03-20

8.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

Authors:  Emely Castro-Rivera; Sophia Ran; Philip Thorpe; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

9.  Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells.

Authors:  Emely Castro-Rivera; Sophia Ran; Rolf A Brekken; John D Minna
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  WNT7a induces E-cadherin in lung cancer cells.

Authors:  Tatsuo Ohira; Robert M Gemmill; Kevin Ferguson; Sophie Kusy; Joëlle Roche; Elisabeth Brambilla; Chan Zeng; Anna Baron; Lynne Bemis; Paul Erickson; Elizabeth Wilder; Anil Rustgi; Jan Kitajewski; Edward Gabrielson; Roy Bremnes; Wilbur Franklin; Harry A Drabkin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.